HUP9904167A3 - 1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the same - Google Patents
1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the sameInfo
- Publication number
- HUP9904167A3 HUP9904167A3 HU9904167A HUP9904167A HUP9904167A3 HU P9904167 A3 HUP9904167 A3 HU P9904167A3 HU 9904167 A HU9904167 A HU 9904167A HU P9904167 A HUP9904167 A HU P9904167A HU P9904167 A3 HUP9904167 A3 HU P9904167A3
- Authority
- HU
- Hungary
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- piperidine derivatives
- disubstituted piperazine
- Prior art date
Links
- -1 1,4-disubstituted piperazine Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67439196A | 1996-07-01 | 1996-07-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9904167A2 HUP9904167A2 (hu) | 2000-05-28 |
| HUP9904167A3 true HUP9904167A3 (en) | 2000-07-28 |
Family
ID=24706404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904167A HUP9904167A3 (en) | 1996-07-01 | 1997-06-26 | 1,4-disubstituted piperazine and piperidine derivatives, their use and pharmaceutical compositions containing the same |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0912534B1 (enExample) |
| JP (2) | JP2000514060A (enExample) |
| KR (1) | KR20000022380A (enExample) |
| AT (1) | ATE224884T1 (enExample) |
| AU (1) | AU717431B2 (enExample) |
| CA (1) | CA2258044C (enExample) |
| DE (1) | DE69715865T2 (enExample) |
| ES (1) | ES2179353T3 (enExample) |
| HU (1) | HUP9904167A3 (enExample) |
| IL (1) | IL127858A0 (enExample) |
| NZ (1) | NZ333322A (enExample) |
| WO (1) | WO1998000412A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726736D0 (en) * | 1997-12-18 | 1998-02-18 | Zeneca Ltd | Chemical compounds |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| AU1874500A (en) * | 1998-12-24 | 2000-07-31 | Astrazeneca Ab | 1,4-diazacycloheptane derivatives useful in the treatment of neurological disorders |
| GB9914015D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
| GB9900078D0 (en) * | 1999-01-05 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
| GB9914022D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
| GB9914025D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
| GB9914024D0 (en) * | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
| US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| EP1453806B1 (en) * | 2001-12-03 | 2007-12-19 | F. Hoffmann-La Roche Ag | Aminotetralin derivatives as muscarinic receptor antagonist |
| CN100349862C (zh) | 2002-11-25 | 2007-11-21 | 先灵公司 | 大麻素受体配体 |
| WO2005037830A1 (en) | 2003-10-10 | 2005-04-28 | Wyeth | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands |
| AU2005234596B8 (en) | 2004-04-13 | 2011-06-16 | Incyte Holdings Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| US7378415B2 (en) | 2004-09-30 | 2008-05-27 | Roche Palo Alto Llc | Benzoxazine and quinoxaline derivatives and uses thereof |
| BRPI0515835A (pt) * | 2004-12-21 | 2008-08-12 | Hoffmann La Roche | derivados de tetralina e de indano e seus usos |
| KR20070121028A (ko) * | 2005-03-29 | 2007-12-26 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 치환된 아미노알킬- 및 아미도알킬-벤조피란 유도체 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| WO2007051735A1 (en) | 2005-11-03 | 2007-05-10 | F. Hoffmann-La Roche Ag | Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
| JP2009541248A (ja) | 2006-06-20 | 2009-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | アリールスルホンアミジルテトラリン誘導体及びそれらの使用 |
| WO2007147763A1 (en) | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Arylsulfonyl naphthalene derivatives and uses thereof |
| KR101066306B1 (ko) | 2006-06-20 | 2011-09-20 | 에프. 호프만-라 로슈 아게 | 테트랄린 및 인데인 유도체 및 이들의 용도 |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| AU2011216950A1 (en) | 2010-02-16 | 2012-08-23 | Pfizer Inc. | (R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| PE20181003A1 (es) * | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
| MX2024000313A (es) | 2021-07-09 | 2024-03-06 | Plexium Inc | Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD113545A5 (enExample) * | 1973-03-30 | 1975-06-12 | ||
| DE3064285D1 (en) * | 1979-09-28 | 1983-08-25 | Beecham Group Plc | Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them |
| DK691488A (da) * | 1987-12-14 | 1989-06-15 | Beecham Group Plc | Hidtil ukendte forbindelser |
| DK286990D0 (da) * | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | Indanderivater |
| PL176250B1 (pl) * | 1991-11-05 | 1999-05-31 | Smithkline Beecham Corp | Sposób wytwarzania pochodnych indanu |
| WO1994012493A1 (en) * | 1992-11-25 | 1994-06-09 | Sandoz, Ltd. | 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals |
-
1997
- 1997-06-26 DE DE69715865T patent/DE69715865T2/de not_active Expired - Fee Related
- 1997-06-26 AU AU34953/97A patent/AU717431B2/en not_active Ceased
- 1997-06-26 ES ES97931281T patent/ES2179353T3/es not_active Expired - Lifetime
- 1997-06-26 KR KR1019980710811A patent/KR20000022380A/ko not_active Withdrawn
- 1997-06-26 CA CA002258044A patent/CA2258044C/en not_active Expired - Fee Related
- 1997-06-26 HU HU9904167A patent/HUP9904167A3/hu unknown
- 1997-06-26 AT AT97931281T patent/ATE224884T1/de not_active IP Right Cessation
- 1997-06-26 NZ NZ333322A patent/NZ333322A/en unknown
- 1997-06-26 EP EP97931281A patent/EP0912534B1/en not_active Expired - Lifetime
- 1997-06-26 JP JP10504196A patent/JP2000514060A/ja not_active Ceased
- 1997-06-26 WO PCT/US1997/010696 patent/WO1998000412A1/en not_active Ceased
- 1997-06-26 IL IL12785897A patent/IL127858A0/xx unknown
-
2008
- 2008-07-28 JP JP2008194199A patent/JP2009040778A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69715865T2 (de) | 2003-08-07 |
| AU3495397A (en) | 1998-01-21 |
| JP2009040778A (ja) | 2009-02-26 |
| KR20000022380A (ko) | 2000-04-25 |
| AU717431B2 (en) | 2000-03-23 |
| ES2179353T3 (es) | 2003-01-16 |
| DE69715865D1 (de) | 2002-10-31 |
| JP2000514060A (ja) | 2000-10-24 |
| CA2258044C (en) | 2007-09-04 |
| CA2258044A1 (en) | 1998-01-08 |
| EP0912534A1 (en) | 1999-05-06 |
| WO1998000412A1 (en) | 1998-01-08 |
| ATE224884T1 (de) | 2002-10-15 |
| HUP9904167A2 (hu) | 2000-05-28 |
| IL127858A0 (en) | 1999-10-28 |
| EP0912534B1 (en) | 2002-09-25 |
| NZ333322A (en) | 2000-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902827A3 (en) | Piperidine and piperazine derivatives as muscarinic antagonists, pharmaceutical compositions containing the same and their use | |
| HUP9700709A3 (en) | 1,2-diphenylpyrrole derivatives, use thereof and pharmaceutical compositions containing these compounds | |
| HUP9800792A3 (en) | Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same | |
| IL116917A0 (en) | Piperidine derivatives and pharmaceutical compositions containing the same | |
| HU0500549D0 (en) | Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof | |
| HUP9901037A3 (en) | Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds | |
| IL111002A0 (en) | Piperidine derivatives, their preparation and pharmaceutical compositions containing them | |
| HUP0003217A3 (en) | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and pharmaceutical compositions containing them | |
| IL104690A0 (en) | Piperazine and piperidine derivatives,their preparation and pharmaceutical compositions containing them | |
| HUT74464A (en) | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them | |
| IL140862A (en) | Thiobenzimidazole derivatives and pharmaceutical compositions containing the same | |
| HUP0003362A3 (en) | Piperidine derivatives and pharmaceutical compositions containing them | |
| HUP0004926A3 (en) | 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring, pharmaceutical compositions containing them and their use | |
| IL110348A0 (en) | Piperazine derivatives and pharmaceutical compositions containing them | |
| IL133097A0 (en) | Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof | |
| HUP9701194A3 (en) | 4-hydroxy-piperidine derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds | |
| AU2529695A (en) | Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists | |
| HUP9904694A3 (en) | Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them | |
| IL113103A0 (en) | Piperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| HUP9904682A3 (en) | Phenyloxazole and -thiazole derivatives, their use and pharmaceutical compositions containing them | |
| HUP0105075A3 (en) | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives, their use and pharmaceutical compositions containing them | |
| IL122981A0 (en) | Piperazine derivatives and their use as 5-HT1A antagonists | |
| HUP9901389A3 (en) | Piperidine and pyrrolidine derivatives acting for the central nervous system, pharmaceutical compositions containing these compounds, preparation and use thereof | |
| HUP0102400A3 (en) | Substituted octalydropyrido[1,2a]pyrazin derivatives and pharmaceutical compositions containing the same | |
| HUP9902668A3 (en) | Piperazine derivatives, pharmaceutical compositions containing them and their use |